Published in Medical Letter on the CDC and FDA, September 18th, 2005
This grants Pegasus Biologics clearance to market its bioimplants to reinforce compromised soft tissues in sports medicine, orthopedic, and spine applications.
Pegasus Biologics, Inc. develops novel bioimplants using proprietary technologies.
This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. Copyright 2005, Medical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.